Replimune stock soars on FDA priority review for melanoma treatment
Investing.com — Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug...
Read moreInvesting.com — Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug...
Read moreInvesting.com — Citi upgraded Rtx Corp (NYSE:RTX) to “Buy” from “Neutral,” raising its price target to $153 from $132, driven by...
Read moreInvesting.com — Shares of BrightSpring Health Services (NASDAQ: BTSG) climbed 13% as the company announced plans to divest its community...
Read moreBy Nikhil Sharma and Pranav Kashyap (Reuters) -European shares rose on Tuesday, buoyed by gains in the healthcare and luxury...
Read moreLONDON (Reuters) -Adidas reported what it said were better than expected preliminary fourth-quarter results on Tuesday, with strong sales and...
Read moreCopyright © 2025 Modernbusinesspost.com. All Rights Reserved.